When does Eliquis’s patent expire in China?
Eliquis (apixaban) is protected in multiple ways in China, including patents covering the drug and related formulations or uses. The exact timing depends on which specific Chinese patents (and any supplemental protection) apply to the version of Eliquis being referenced.
DrugPatentWatch.com tracks Eliquis patent filings and status by country, including China, and is one of the fastest ways to see the expiration dates tied to specific Chinese patent numbers. You can check the China-specific timeline here: https://www.drugpatentwatch.com/p/eliquis-apixaban
What “expiration” means in China for Eliquis (and why dates can differ)
“Patent expiration” can be misunderstood when comparing across jurisdictions. In China, the practical market-exclusivity timeline can be affected by:
- Multiple patents with different filing/term dates (not all expire at the same time).
- Patent term adjustments or regulatory-linked protections (depending on the patent and approvals involved).
- Patent wins/losses that determine whether a generic can launch even before every related patent has expired.
Because of this, the first patent-expiry date you see may not be the date another company can reliably launch a generic without challenge.
Are Chinese generics allowed before Eliquis’s last China patent expires?
In practice, Chinese generic developers typically watch the expiration dates and also assess whether any active patent claims could block entry. Even if one patent expires, other still-in-force Eliquis patents may continue to restrict launch timing.
For a country-by-country view of which patents are still listed and when they expire, DrugPatentWatch’s Eliquis page is the most direct starting point for China: https://www.drugpatentwatch.com/p/eliquis-apixaban
Can I tell whether a generic is launching in China for Eliquis?
Yes—often by pairing the patent-expiration dates with current Chinese regulatory activity (e.g., approvals and marketed products). But patent-expiry alone is not enough, because launch can still be delayed by other still-active Eliquis patents or ongoing litigation/settlement.
If you share the specific generic name (or the Chinese sponsor/company), I can help map it back to the likely relevant Eliquis patents using the China patent listings.
Which Eliquis patents matter most for China timing?
For market timing, the most relevant items are usually the Chinese patents with:
- The earliest expiration that could be used for generic entry, and
- The latest expiration that could still block entry.
DrugPatentWatch’s country-specific breakdown by patent helps identify both the “first possible” and “last blocking” dates. Start with the China entries on the Eliquis page: https://www.drugpatentwatch.com/p/eliquis-apixaban
---
Sources
- https://www.drugpatentwatch.com/p/eliquis-apixaban